LBA
AURA icon

Letko, Brosseau & Associates’s Aura Biosciences AURA Stock Holding History

Letko, Brosseau & Associates’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Hold
28,300
– – ﹤0.01% 105
2026
Q1 		$189K Hold
28,300
– – ﹤0.01% 93
2025
Q4 		$154K Hold
28,300
– – ﹤0.01% 93
2025
Q3 		$175K Buy
28,300
+7,100
+33% +$46.4K ﹤0.01% 91
2025
Q2 		$133K Hold
21,200
– – ﹤0.01% 89
2025
Q1 		$124K Hold
21,200
– – ﹤0.01% 83
2024
Q4 		$174K Hold
21,200
– – ﹤0.01% 94
2024
Q3 		$189K Hold
21,200
– – ﹤0.01% 95
2024
Q2 		$160K Hold
21,200
– – ﹤0.01% 98
2024
Q1 		$166K Buy
+21,200
New +$176K ﹤0.01% 96

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Letko, Brosseau & Associates's AURA Position: Q2 2026 in Review

Letko, Brosseau & Associates held its Aura Biosciences (AURA) position steady in Q2 2026 at 28,300 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #105.

Letko, Brosseau & Associates first reported a position in AURA in Q1 2024 and has held it in 10 quarters since. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Letko, Brosseau & Associates held 28,300 shares of Aura Biosciences worth $201K as of Q2 2026.
  • Letko, Brosseau & Associates left its Aura Biosciences share count unchanged in Q2 2026.
  • Aura Biosciences made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #105 holding.
  • Letko, Brosseau & Associates first reported a position in Aura Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.